VK2735
Also known as: VK-2735
Classification
Peptide
Regulatory Status
not-established
Sources
3
Review
n/a
Overview
VK2735 is an investigational dual agonist of the GLP-1 and GIP receptors being developed by Viking Therapeutics in weekly subcutaneous and oral formulations for weight management.
Evidence and limitations
Human/preclinical evidence breakdown is not available in this record.
Pathways
Benefits
Studied in sponsor-funded Phase 2 trials for weight management and advanced into Phase 3 programs; not FDA-approved and not available as a legitimate commercial consumer product.
Interactions & cautions
Drug interactions
insulin or insulin secretagogues — Hypoglycemia risk possible if combined in diabetes contexts (review)
other GLP-1 or dual GIP/GLP-1 agonists — Additive GI and metabolic effects likely (review)
These are observational flags for review, not individualized instructions.
Sources
Educational reference only — not medical advice.
What people report (anecdote)
CLINICAL DATA (from trials)
Adverse events:
None recorded in our sources.
Effects measured:
Human trials: none found.
ANECDOTE
What people report: anecdote, not evidence
Loading…
Submit a claim you saw